Literature DB >> 30804612

18F-FDG PET/CT performed immediately after percutaneous ablation to evaluate outcomes of the procedure: preliminary results.

Juliana Romanato1, Marcos Roberto Menezes1, Allan de Oliveira Santos1,2, Regis Otaviano Franca Bezerra1, Mariana Cunha Lopes Lima1,2, Elba Etchebehere1,2.   

Abstract

OBJECTIVE: To determine whether 18F-fluorodeoxyglucose positron emission tomography/computed tomography performed immediately after percutaneous ablation (iPA 18F-FDG PET/CT) is useful in evaluating the outcomes of the procedure.
MATERIALS AND METHODS: This was a retrospective study of 20 patients (13 males, 7 females; mean age, 65.8 ± 12.1 years) submitted to percutaneous ablation of metastases. All of the lesions treated had shown focal uptake on a 18F-FDG PET/CT scan obtained at baseline. The primary tumors were mainly colorectal cancer (in 45%) or lung cancer (in 40%). iPA 18F-FDG PET/CT was performed to identify any residual viable tumor cells. The treatment was considered a success (no viable tumor cells present) if no uptake of 18F-FDG was noted on the iPA 18F-FDG PET/CT scan.
RESULTS: Twenty-six lesions were submitted to percutaneous ablation with either cryoablation (n = 7) or radiofrequency ablation (n = 19). The mean lesion diameter was 2.52 ± 1.49 cm. For the detection of viable tumor cells, iPA 18F-FDG PET/CT had a sensitivity, specificity, accuracy, positive predictive value, and negative predictive value of 66.7%, 95%, 88.5%, 80%, and 90.5%, respectively. There was a significant correlation between the iPA 18F-FDG PET/CT findings and the results of the follow-up studies (kappa = 0.66; p < 0.01).
CONCLUSION: iPA 18F-FDG PET/CT studies appear to constitute a useful means of evaluating the outcomes of percutaneous ablation. By detecting residual viable tumor cells, this strategy might allow early re-intervention, thus reducing morbidity. Studies involving larger numbers of patients are needed in order to confirm our findings.

Entities:  

Keywords:  Ablation techniques; Cryosurgery/methods; Fluorodeoxyglucose F18; Positron-emission tomography/methods; Radiofrequency ablation; Tomography, X-ray computed/methods

Year:  2019        PMID: 30804612      PMCID: PMC6383533          DOI: 10.1590/0100-3984.2018.0010

Source DB:  PubMed          Journal:  Radiol Bras        ISSN: 0100-3984


  24 in total

Review 1.  Radiofrequency ablation of the liver: current status.

Authors:  J P McGhana; G D Dodd
Journal:  AJR Am J Roentgenol       Date:  2001-01       Impact factor: 3.959

Review 2.  Image-guided radiofrequency ablation as a new treatment option for patients with lung cancer.

Authors:  Namita S Gandhi; Damian E Dupuy
Journal:  Semin Roentgenol       Date:  2005-04       Impact factor: 0.800

Review 3.  How much CT do we need for PEt/CT? A radiologist's perspective.

Authors:  H Kuehl; G Antoch
Journal:  Nuklearmedizin       Date:  2005       Impact factor: 1.379

4.  Radiofrequency ablation of primary lung cancer: results from an ablate and resect pilot study.

Authors:  Christophe L Nguyen; Walter J Scott; Nancy A Young; Tina Rader; Lydia R Giles; Melvyn Goldberg
Journal:  Chest       Date:  2005-11       Impact factor: 9.410

5.  Detection of residual tumor after radiofrequency ablation of liver metastasis with dual-modality PET/CT: initial results.

Authors:  Patrick Veit; Gerald Antoch; Hrvoje Stergar; Andreas Bockisch; Michael Forsting; Hilmar Kuehl
Journal:  Eur Radiol       Date:  2005-05-03       Impact factor: 5.315

6.  Office-based ultrasound-guided cryoablation of breast fibroadenomas.

Authors:  Cary S Kaufman; Barbara Bachman; Peter J Littrup; Michael White; Kathryn A Carolin; Laurie Freman-Gibb; Darius Francescatti; Lewis H Stocks; J Stanley Smith; C Alan Henry; Lisa Bailey; Jay K Harness; Rache Simmons
Journal:  Am J Surg       Date:  2002-11       Impact factor: 2.565

Review 7.  Evaluation of liver metastases after radiofrequency ablation: utility of 18F-FDG PET and PET/CT.

Authors:  David W Barker; Ronald J Zagoria; Kathryn A Morton; Peter V Kavanagh; Perry Shen
Journal:  AJR Am J Roentgenol       Date:  2005-04       Impact factor: 3.959

8.  Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET.

Authors:  Gerald Antoch; Nina Saoudi; Hilmar Kuehl; Gerlinde Dahmen; Stefan P Mueller; Thomas Beyer; Andreas Bockisch; Jörg F Debatin; Lutz S Freudenberg
Journal:  J Clin Oncol       Date:  2004-11-01       Impact factor: 44.544

9.  [F-18] fluorodeoxyglucose positron emission tomography as a tool for early recognition of incomplete tumor destruction after radiofrequency ablation for liver metastases.

Authors:  Vincent Donckier; Jean Luc Van Laethem; Serge Goldman; Daniel Van Gansbeke; Pascale Feron; Brigitte Ickx; David Wikler; Michel Gelin
Journal:  J Surg Oncol       Date:  2003-12       Impact factor: 3.454

10.  Percutaneous radiofrequency ablation of lung neoplasms: initial therapeutic response.

Authors:  Masao Akeboshi; Koichiro Yamakado; Atsuhiro Nakatsuka; Osamu Hataji; Osamu Taguchi; Motoshi Takao; Kan Takeda
Journal:  J Vasc Interv Radiol       Date:  2004-05       Impact factor: 3.464

View more
  3 in total

Review 1.  Cryoablation of Lung Metastases: Review of Recent Literature and Ablation Technique.

Authors:  Patrick W Eiken; Brian T Welch
Journal:  Semin Intervent Radiol       Date:  2019-10-31       Impact factor: 1.513

2.  Use of PET/CT to aid clinical decision-making in cases of solitary pulmonary nodule: a probabilistic approach.

Authors:  Felipe Alves Mourato; Ana Emília Teixeira Brito; Monique Sampaio Cruz Romão; Renata Guerra Galvão Santos; Cristiana Altino de Almeida; Paulo José de Almeida Filho; Aline Lopes Garcia Leal
Journal:  Radiol Bras       Date:  2020 Jan-Feb

3.  Image guided ablation.

Authors:  Xinrui Zhang; Andreas Melzer
Journal:  Scott Med J       Date:  2021-11       Impact factor: 0.729

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.